Danish diabetes giant Novo Nordisk (NOV: N) today reported financial results for the first quarter of 2024, noting that sales ...

Subsidies for Danish drugmaker giant Novo Nordisk’s diabetes drug Ozempic (semaglutide) will be restricted in its home country due to rising public spending on the blockbuster diabetes medicine, which ...

San Diego, USA-based clinical-stage cell and gene therapy company Poseida Therapeutics (Nasdaq: PSTX) saw its shares close up more than 20% at $2.92 yesterday, when it revealed a second ...

Californian biotech Enlaza Therapeutics has raised $100 million in a series A financing led by J.P. Morgan Asset Management’s Private Capital division.

Sanofi’s (Euronext: SAN) Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalizations by 82% in infants under six months of age, compared to babies who received no RSV ...

UK clinical-stage biotech Barinthus Biotherapeutics, formerly Vaccitech, today announced the appointment of Dr Leon Hooftman as chief medical officer (CMO).

Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify and optimize novel macrocyclic peptides against targets ...

This increased understanding of disease biology is allowing argenx and other biotech companies to develop medicines that block IgG recycling by FcRn and may result in new treatment options for people ...

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, has appointed Ashley Nagle as chief business officer (CBO) with immediate effect as part of a broader ...

There are no items. UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, has appointed Ashley Nagle as chief business officer (CBO) with immediate effect as part ...

Along with all the other medicines supply problems that the country has recently encountered, Russia is now facing a shortage of anti-HIV drugs, despite a significant increase of their procurements by ...

US pharma giant Merck & Co has announced results from STRIDE-10, a Phase III trial of V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine (PCV), at the ...